Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis

Karin Sharona Leder; L H Chen; Mary E Wilson

doi:10.1016/j.vaccine.2011.12.133

Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis

Karin Sharona Leder
, L H Chen
, Mary E Wilson

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

38 Citations (Scopus)

Abstract

Vaccine recommendations for travellers are based on individual risk assessments of multiple factors, most importantly the destination and duration of the impending trip. Many people undertake frequent trips, but existing WHO, CDC and national advisory board recommendations do not explicitly consider cumulative travel-associated risks. Given the period of protection provided by many vaccines, in particular rabies, hepatitis A, hepatitis B and yellow fever vaccines, an aggregate multi-trip risk assessment which views vaccines as an investment for future travel health may be more appropriate than separately evaluating the risks for each trip.

Original language	English
Pages (from-to)	2600-2604
Number of pages	5
Journal	Vaccine
Volume	30
Issue number	15
DOIs	https://doi.org/10.1016/j.vaccine.2011.12.133
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.vaccine.2011.12.133

Cite this

@article{fefa2131c5814ebb86b17a8d536ab562,

title = "Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis",

abstract = "Vaccine recommendations for travellers are based on individual risk assessments of multiple factors, most importantly the destination and duration of the impending trip. Many people undertake frequent trips, but existing WHO, CDC and national advisory board recommendations do not explicitly consider cumulative travel-associated risks. Given the period of protection provided by many vaccines, in particular rabies, hepatitis A, hepatitis B and yellow fever vaccines, an aggregate multi-trip risk assessment which views vaccines as an investment for future travel health may be more appropriate than separately evaluating the risks for each trip.",

author = "Leder, \{Karin Sharona\} and Chen, \{L H\} and Wilson, \{Mary E\}",

year = "2012",

doi = "10.1016/j.vaccine.2011.12.133",

language = "English",

volume = "30",

pages = "2600--2604",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "15",

}

TY - JOUR

T1 - Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis

AU - Leder, Karin Sharona

AU - Chen, L H

AU - Wilson, Mary E

PY - 2012

Y1 - 2012

N2 - Vaccine recommendations for travellers are based on individual risk assessments of multiple factors, most importantly the destination and duration of the impending trip. Many people undertake frequent trips, but existing WHO, CDC and national advisory board recommendations do not explicitly consider cumulative travel-associated risks. Given the period of protection provided by many vaccines, in particular rabies, hepatitis A, hepatitis B and yellow fever vaccines, an aggregate multi-trip risk assessment which views vaccines as an investment for future travel health may be more appropriate than separately evaluating the risks for each trip.

AB - Vaccine recommendations for travellers are based on individual risk assessments of multiple factors, most importantly the destination and duration of the impending trip. Many people undertake frequent trips, but existing WHO, CDC and national advisory board recommendations do not explicitly consider cumulative travel-associated risks. Given the period of protection provided by many vaccines, in particular rabies, hepatitis A, hepatitis B and yellow fever vaccines, an aggregate multi-trip risk assessment which views vaccines as an investment for future travel health may be more appropriate than separately evaluating the risks for each trip.

UR - http://www.sciencedirect.com/science/article/pii/S0264410X11020949

U2 - 10.1016/j.vaccine.2011.12.133

DO - 10.1016/j.vaccine.2011.12.133

M3 - Article

SN - 0264-410X

VL - 30

SP - 2600

EP - 2604

JO - Vaccine

JF - Vaccine

IS - 15

ER -

Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis

Abstract

UN SDGs

Access to Document

Other files and links

Improving knowledge regarding the burden of infection associated with water exposure and with international travel: addressing data gaps to improve policy and practice

Cite this

Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis

Abstract

UN SDGs

Access to Document

Other files and links

Projects

Improving knowledge regarding the burden of infection associated with water exposure and with international travel: addressing data gaps to improve policy and practice

Cite this